Read More

XPO’s Winning Strategy: Analyst Highlights Service Improvements and Aggressive Acquisitions Fueling Growth

Oppenheimer analyst Scott Schneeberger reiterated an Outperform rating on the shares of XPO and raised the price target from $90 to $100. XPO's two-year strategic shift toward enhanced customer service has garnered 2023 market share gains, analyst says.

XPO

Read More

Cytokinetics’ Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst

Novartis halts pursuit of Cytokinetics acquisition, impacting promising heart drug. Analysts estimate $3.6 billion sales for Cytokinetics' cardiomyopathy drug by 2032. Still lead drug aficamten viewed as a distinctive therapy for Hypertrophic Cardiomyopathy.

AZN